Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B

Chan Young Jung, Hyung Woo Kim, Sang Hoon Ahn, Seung Up Kim, Beom Seok Kim

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background and Aims: Entecavir (ETV) and tenofovir alafenamide (TAF) are the preferred agents in patients with predisposing factors for nephrotoxicity, but no studies to date have directly compared the renal safety of the two antiviral agents. Hence, we compared the risk of kidney function decline among patients with treatment-naïve chronic hepatitis B (CHB) treated with ETV or TAF. Methods: This study included 1988 patients with treatment-naïve CHB who were treated with ETV (n = 1839) or TAF (n = 149) between 2007 and 2020 for ETV and between 2017 and 2020 for TAF. The primary outcome was chronic kidney disease (CKD) progression, defined as an increase in CKD stage by at least one stage for at least three consecutive months. Results: A 1:1 propensity score match yielded 149 patients in each treatment group. The mean estimated glomerular filtration rate (eGFR) was 100.6 ml/min/1.73 m2 vs. 101.3 ml/min/1.73 m2 in the ETV and TAF groups respectively. A total of 61 patients developed a progression in CKD stage ≥ 1, of which 47 and 14 patients were from the ETV- and TAF-treated groups respectively (19.9 vs. 5.1 per 1000 person-years; p <.001). The risk of progression in CKD stage ≥1 was significantly higher in patients treated with ETV, even when adjusted for potential confounders (adjusted hazard ratio 4.05; 95% CI 2.14–7.68; p <.001). Conclusions: ETV was associated with a higher risk of kidney function decline than TAF in patients with treatment-naïve CHB. Therefore, further prospective randomized studies are needed.

Original languageEnglish
Pages (from-to)1017-1026
Number of pages10
JournalLiver International
Issue number5
Publication statusPublished - 2022 May

Bibliographical note

Funding Information:
Seung Up Kim has served as an advisory committee member of Gilead Sciences, Bayer, Eisai and Novo Nordisk. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, AbbVie, EchoSens, MSD, Eisai, Otsuka and Bristol‐Myers Squibb. He has also received a research grant from AbbVie and Bristol‐Myers Squibb. The other authors declare that they have no competing interests.

Funding Information:
Funding information This study was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2019R1A2C4070136). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

Publisher Copyright:
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

All Science Journal Classification (ASJC) codes

  • Hepatology


Dive into the research topics of 'Higher risk of kidney function decline with entecavir than tenofovir alafenamide in patients with chronic hepatitis B'. Together they form a unique fingerprint.

Cite this